mortality at 30 days, with one death in a patient with functional MR after 5.8 years and a degenerative MR patient after 3.2 years. There were no strokes with an average follow-up of 2.4AE1.8 years. There were sustained improvements in New York Heart Association class (from 2.8 AE 0.6 to 1.6 AE 0.5, p <0.001) and MR grade (from 3.5 AE 0.9 to 0.4 AE 0.5, p <0.001) at follow-up. Conclusions: In this large single center experience, no patient required urgent cardiac surgery for failed MitraClip procedure. Mitral valve repair rate in patients with degenerative MR was high, and surgical options were preserved in the remaining patients. Overall, cardiac surgical outcomes were excellent.
Background:
In primary or degenerative mitral regurgitation (DMR), the mitral valve (MV) leaflets are structurally abnormal. The MitraClip device is the only percutaneous leaflet-based therapy evaluated by both randomized and registry-based studies utilizing core lab evaluation of patients with moderate to severe or severe (! 3+) DMR. Functional MR has been separately and previously evaluated. Methods: One-year data from the EVEREST II studies were analyzed for 509 patients with severe baseline DMR, including 447 treated with MitraClip and 62 who underwent a first MV surgery. Results: MV leaflet pathologies of prolapse and flail were well-represented. Compared to surgical candidates, high-risk DMR patients had STS mortality risk scores of !12%, or surgeon assessment of excessive risk based on pre-specified factors. They were older, more frequently had serious baseline co-morbidities, and had more severe functional impairment than DMR patients in the RCT (Table 1) . Implant rates were consistently high across MitraClip DMR cohorts. Safety outcomes reflected patient risk status. Lower-risk DMR patients who underwent MV surgery had more complete MR reduction and greater improvement in LV volumes than did lower-risk DMR patients who received MitraClip. Despite their burden of co-morbidities, a large proportion of high-risk DMR patients who received MitraClip achieved and maintained MR reduction to 2+ or less and did not undergo MV surgery. Background: Following CE approval in 2008, percutaneous mitral valve repair with the MitraClip system (Abbott) has entered clinical practice in Europe, where it is predominantly used to treat patients (pts) at high surgical risk. We sought to assess, and elucidate the interrelation of, baseline echocardiographic variables predictive of acute procedural failure in such pts. Methods: The first 300 consecutive pts (75 AE 9 years, 190 men [63%]) who underwent MitraClip therapy for grade 3+/4+ mitral regurgitation (MR) at our institution comprised the study cohort. All pts were adjudicated by heart team consensus as not amenable to surgery. Procedural failure, defined as discharge MR !3+, was encountered in 32 patients (10.7%), with 11 aborted procedures (no clip implanted) and 21 clip failures (MR !3+ despite clip implantation). Results: Exact logistic regression analysis identified effective regurgitant orifice area (EROA), mitral valve orifice area (MVOA), mean transmitral pressure gradient (TPG), and MR severity (not quantified via EROA) as predictive of failure. Classification tree analysis (Figure) revealed EROA as the variable with highest discriminatory power, followed by MVOA, TPG and MR severity. The highest incidence of clip failures occurred in pts with EROA >0.71cm2, highest incidence of aborted procedures in pts with MVOA 3.0cm2 and TPG !4mmHg.
Conclusions: Baseline echocardiographic variables differentially impact the procedural outcome of MitraClip therapy. Classification tree analysis clarifies their interrelationship and may help to reduce the procedural failure rate.
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MitraClip-Induced Acute Changes in Renal Function Impact Mortality in Surgical High-Risk Patients with Significant Mitral Regurgitation
Edith Lubos 1 , Daniel Lubs 1 , Michael Schlüter 1 , Mareike Donner 1 , Georg Sander 1 , Johannes Schirmer 1 , Lenard Conradi 1 , Hendrik Treede 1 , Hermann Reichenspurner 1 , Stephan Baldus 2 , Volker Rudolph 2 , Stefan Blankenberg 1 , Britta Goldmann 1 1 University Heart Center Hamburg, Hamburg, Germany, 2 University Hospital of Cologne, Cologne, Germany
Background: Impaired renal function (RF) is strongly associated with poor outcome in patients (pts) with chronic heart failure (HF). We sought to assess the acute effect of MitraClip therapy (MC) on RF and its impact on mortality and HF rehospitalization. Methods: In a retrospective analysis of 306 surgical high-risk pts (74.4 AE 8.7 years, 197 men [64.4%]) with !grade 3+ mitral regurgitation (MR) treated by MC, we calculated glomerular filtration rate (GFR) at baseline (BL) and discharge from creatinine levels (CKD-EPI formula). GFR was converted into the 5 Kidney Disease Outcomes Quality Initiative (KDOQI) stages. Pts were followed for 16 AE 11 (range, 0.3-41) months. Results: MC acutely improved RF (DKDOQI <0) in 82 pts (27%) and worsened RF (DKDOQI >0) in 31 pts (10%), with no change in 63% of pts. Overall, survival was Background: Transcatheter mitral valve-in-valve / valve-in-ring implantation is an emerging therapeutic alternative for patients with failed mitral valves after surgical intervention and may obviate the need for a redo operation. We aimed to evaluate the clinical results of this technique using a large worldwide registry. Methods: The registry included 134 patients with degenerated mitral valves after surgical intervention (12.7% ring only, median of 9 years post procedure) from 22 centers. Mean age 74.3 AE 11 years; 64.4% female (STS score 16.1 AE 13.1%). The mode of failure was regurgitation (n¼64, 47.8%), stenosis (n¼34, 25.4%), and combined stenosis and regurgitation (n¼36, 26.9%). Results: Transcatheter Edwards SAPIEN (Edwards Lifesciences, Irvine, CA) implantation was performed in all cases (23 mm in 15.7%, 26 mm in 58.2%, and 29 mm in 26.1%). Procedural access was transapical in 117 cases (87.3%); transseptal in 12 (9%), and through the left atrium via right mini-thoracotomy in 5 (3.7%). Twenty combined procedures (14.9%) included aortic valve-in-valves, aortic valve replacement, tricuspid valve-in-ring implantation, and paravalvular leak closure. Device malposition appeared in 6 cases (4.5% of cases) and post implantation valvuloplasty was utilized in 8%. Post-procedure, mitral valve area was 2 AE 0.6 cm2, valve maximum / mean gradients were 13 AE 6.3 mmHg / 6.4 AE 3, respectively, and significant mitral regurgitation (!+2) was observed in 5.2% of patients. Median length of hospital stay was 7 days. At 30-day follow-up, all-cause mortality was 8.2%, 1.5% of patients had stroke and 79.2% were at New York Heart Association functional class I/II. Conclusions: Mitral valve-in-valve/ valve-in-ring implantations, performed in extremely high-risk patients, were clinically effective in most patients with degenerative mitral valves after surgery. The safety and efficacy of this approach will be further examined. Background: Elderly patients with severe mitral regurgitation (MR) often present with multiple serious co-morbidities including heart failure (HF), and therefore are not considered candidates for mitral valve surgery due to high risk of surgical mortality and morbidity. These patients have limited options as no medical therapy is directed specifically at reducing MR. The MitraClip system has emerged as an important non-surgical treatment option. Results in the high risk octogenarian cohort treated with MitraClip in the EVEREST II studies have not been presented. Methods: High risk patients age !80 years had 3+/4+ MR at baseline and were deemed high risk for surgery as predicted by STS mortality risk score of !12%, or surgeon assessment based on pre-specified factors. Echocardiograms were evaluated by an independent core lab. Clinical outcomes at 1 year including change in left ventricular (LV) volume, NYHA class, quality of life (QoL), and hospitalizations for HF were analyzed. Results: A total of 146 high risk octogenarians (mean age 85 yrs) underwent the MitraClip procedure. Baseline co-morbidities included CAD (80%), prior CABG (47%) and moderate to severe renal disease (33%). Baseline LVEF was 52AE14%. Predicted mortality (STS risk score) was 15AE8%. Actual 30-day mortality was 7.5%. Despite advanced age and burden of co-morbidities, 84% of octogenarians achieved MR reduction to 2+ post-MitraClip and 90% were discharged home. At 1 year, octogenarians showed improvements from baseline in clinical and functional measures (Table 1) .
Conclusions:
In high risk octogenarians, the MitraClip procedure resulted in meaningful improvements in MR severity, LV volumes and QoL. Percutaneous reduction of MR with the MitraClip is a therapeutic option for high risk elderly patients with multiple co-morbidities who are not candidates for surgery. 
